BBTV Reaches Nearly Half A Trillion Annual Views
News provided by
Share this article
1
VANCOUVER, BC, Jan. 29, 2021 /PRNewswire/ - BBTV Holdings Inc. (TSX: BBTV), a media tech company that uses technology enabled solutions to help content creators become more successful, unveils that its video content is now viewed monthly by more than 600 million unique viewers
2 with almost half a trillion annual views
1.
Annual views grew by 50 billion during the year from 423 billion in 2019 to 473 billion in 2020
1, equating to growth of more than four billion views per month.
The growth rate for annual views accelerated in 2020 with a growth rate of 12% year-over-year, up from 4% in 2019
Share this article
Share this article
CAMDEN, N.J., Jan. 28, 2021 /PRNewswire/ Subaru of America, Inc. today announced that the Human Rights Campaign has awarded the automaker a score of 100 percent on its Corporate Equality Index, making it the fifth consecutive year and eighth year overall that SOA has earned top marks on the nation s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ workplace equality.
Subaru of America, Inc. Earns 100 Percent in 2021 Corporate Equality Index for Fifth Consecutive Year; Automaker Earns Perfect Score on the Human Rights Campaign Scorecard on LGBTQ Workplace Equality A commitment to diversity, equity and inclusion is a key value that makes us more than a car company, and we are proud to be recognized once again by CEI as a Best Place to Work, said Thomas J. Doll, President and CEO, Subaru of America, Inc. We look forward to continuing to advance diversity, cultivate equality and to live the
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low .
VALNEVAJanuary 25, 2021 GMT
Saint-Herblain (France), Sao Paulo, (Brazil), January 25, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development, manufacturing and marketing of Valneva’s single-shot chikungunya vaccine, VLA1553, in Low and Middle Income Countries (LMICs). This finalization follows the signing of a binding term sheet in May 20201. The collaboration falls within the framework of the $23.4 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 20192.
SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development, manufacturing and marketing of Valneva’s single-shot chikungunya vaccine, VLA1553, in Low and Middle Income Countries (LMICs). This finalization follows the signing of a binding term sheet in May 2020
1. The collaboration falls within the framework of the $23.4 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2019
2.
Under the collaboration, Valneva will transfer its chikungunya vaccine technology to Instituto Butantan, who will develop, manufacture and commercialize the vaccine in LMICs. In addition, Instituto Butantan will provide certain clinical and Phase 4 observational studies that Valneva will use to meet regulatory requireme